▟ Vinebot intrinsic value, daily

← back

BAX Baxter International

healthcare · valued with opus low conviction · deep-dived 2026-10-07

HOLD
Intrinsic value$13.84
Price (at call)$24.36
Margin of safety -43.2%
vs market (rating basis) -16.9%

A broken hospital-supply franchise priced for distress; value hinges entirely on margins recovering to about 13%.

The story

Baxter is a mature, diversified hospital-products company (IV solutions and pumps, injectables, surgical products, Hillrom beds and connected care) that has sold its kidney business to pay down debt after the Hillrom acquisition. It has real scale and an installed-base moat in hospital infusion and IV fluids. Execution problems have repeatedly hurt it: impairments, supply disruptions, and setbacks with the Novum pump have pushed GAAP margins below zero. It is a low-growth turnaround whose value depends on getting margins back to normal for a med-tech company, not on growth.

GAAP margins are depressed by impairments and one-time charges. Adjusted margins have run in the mid-teens, so I assume they recover over 4 years to about 13.5%, roughly where diversified hospital-supply peers settle after amortization. Growth stays close to its 3-4% history. Incremental sales-to-capital of 1.2 is above the 0.74 historical figure because that ratio is inflated by Hillrom goodwill. Beta sits slightly above the 0.9 industry anchor, and failure risk is modest, both reflecting about $7.5B of net debt.

Value drivers

Revenue growth (Y1)3.0%
Terminal growth2.5%
Forecast horizon6y
Target operating margin13.5%
Years to target margin4
Sales-to-capital1.20
Beta0.95
Failure probability5.0%
Cost of capital (WACC)7.7%
Terminal WACC7.9%

Valuation bridge

PV of explicit FCFF3.03B
PV of terminal value11.98B
Equity value7.15B
÷ shares → per share$13.84

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 11.81B 3.0% 2.1% 198.43M 286.75M -88.32M -81.97M
2 12.16B 2.9% 5.9% 568.29M 285.51M 282.79M 243.61M
3 12.50B 2.8% 9.7% 958.51M 283.66M 674.85M 539.58M
4 12.83B 2.7% 13.5% 1.37B 281.18M 1.09B 807.11M
5 13.17B 2.6% 13.5% 1.40B 278.08M 1.13B 775.76M
6 13.50B 2.5% 13.5% 1.44B 274.34M 1.17B 744.85M

Key risks

  • Margin recovery stalls because of further pump or quality failures, FDA actions, or new impairments
  • Leverage of about $7.5B net debt magnifies any operating miss for equity holders
  • Pricing pressure from hospitals and GPOs, plus generic injectables competition, limits growth

Catalysts

  • Novum IQ pump relaunch and gains in infusion-system share
  • Deleveraging and cost restructuring that lift adjusted margins back above 15%

History

DatePriceIntrinsicMoSRating
2026-10-07$24.36 $13.84 -43.2% HOLD
2026-08-18$25.91 $0.00 -100.0% STRONG SELL
2026-06-26$21.55 $11.99 -44.4% HOLD
2026-06-23$20.10 $4.06 -79.8% STRONG SELL